Latest Tardive dyskinesia Stories
ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010. The case is Susan Swicegood v. Pliva et. al.
Reglan, metoclopramide never approved for use in infants HOUSTON, May 3 /PRNewswire-USNewswire/ -- Recently, researchers have observed a disturbing trend in neonatal units across the country: doctors prescribing Reglan -- also known by its generic name, metoclopramide -- to treat premature infants.
SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining XeominÂ® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada.
Informs Public of Serious Risks Associated with Use of Reglan and Metoclopramide: Provides Solutions for Legal Recourse HOUSTON, March 9 /PRNewswire-USNewswire/ -- Blizzard, McCarthy & Nabers, one of the nation's leading pharmaceutical litigation firms is proud to announce the launch of ReglanJustice.com, an educational website aimed at informing consumers of the risks associated with the use of the drug Reglan, and its generic form, metoclopramide.
Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal study.
Clinical study seeks to validate dyskinesia clinical scales, lowering hurdle to industry investment in new treatments NEW YORK, Dec. 21 /PRNewswire-USNewswire/ -- The Michael J.
SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.
INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today.
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGAÂ® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDALÂ® CONSTAÂ®, according to new data from a comparative study of both treatments in patients with schizophrenia.
- The word or words serving to define another word or expression, as in a dictionary entry.